News & Updates
As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete response rate and sustained durability in patients, including those previously exposed to CAR T therapy 100% ORR and CR rate in four anti-CD19 CAR T relapsed patients ADI-001 continued to demonstrate a favorable safety and tolerability profile Clinical…
Read More
TruGraf® Liver is a novel gene expression biomarker diagnostic test used to confirm immune quiescence and rule out organ rejection for liver transplant recipients. Excerpt from the Press Release: FRAMINGHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, will be attending The…
Read More
Biomarker data demonstrates proof-of-concept for KP104’s dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies Excerpt from the Press Release: CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ — Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today presented…
Read More
XPHOZAH monotherapy lowers serum phosphorus with early responders maintaining response with continued treatment XPHOZAH monotherapy meaningfully reduced serum phosphorus in patients with severe hyperphosphatemia XPHOZAH in combination with phosphate binders reduced patients’ interdialytic weight gain compared to binders alone Excerpt from the Press Release: WALTHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a…
Read More
In healthy volunteers, OCE-205 administration led to increases in mean arterial pressure with promising safety profile Study findings support clinical program for OCE-205 in End-Stage Liver Disease focused on treating consequences associated with complications of portal hypertension, such as HRS-AKI and ascites Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ocelot Bio, Inc., a clinical-stage biopharmaceutical…
Read More
Excerpt from the Press Release: BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical…
Read More
3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose Standards Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that its 3Dimensions™ mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening…
Read More
Excerpt from the Press Release: A team of researchers at the University of Washington School of Medicine (UWSM) has been working on a breast cancer vaccine for over the last 20 years. In their recently published study, they finally revealed the results of the phase one human trials of their breast cancer vaccine. A WHO…
Read More
– Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients – – Drug safety profile of milademetan preliminarily consistent with prior Phase 1 trial – – Protocol amendment planned to…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease, today announced new preclinical data demonstrating proof-of-concept for AB359 as a novel immunotherapy approach for chronic HBV. AB359 is…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?